Description
Summary Information: Erleva is a medication provided in the form of oral tablets, containing the active substance Erlotinib. Each tablet typically contains 150 mg of Erlotinib. Erleva is primarily used in the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer. Erlotinib belongs to a class of medications known as tyrosine kinase inhibitors (TKIs), which work by blocking the action of the epidermal growth factor receptor (EGFR), a protein involved in the growth and spread of cancer cells.
Product Composition: The active pharmaceutical ingredient in Erleva tablets is Erlotinib. Erlotinib selectively inhibits the tyrosine kinase activity of the EGFR, thereby blocking the signaling pathways that promote cancer cell growth and survival. In addition to Erlotinib, Erleva tablets may contain various excipients and coatings to ensure proper formulation and stability.
Manufacturer: Erleva tablets are manufactured by Glenmark Pharmaceuticals, a multinational pharmaceutical company known for producing a wide range of high-quality generic medications and innovative pharmaceutical formulations. Glenmark Pharmaceuticals is committed to ensuring product efficacy, safety, and compliance with regulatory standards.
Package: Erleva tablets are typically supplied in packs containing 30 tablets, each with a dosage strength of 150 mg of Erlotinib. The packaging may include information such as the expiration date, lot number, and manufacturer details.
Usage Instructions: Erleva tablets are taken orally with water, usually once daily, or as directed by a healthcare professional. The dosage and duration of treatment may vary depending on factors such as the type and stage of cancer, EGFR mutation status, and individual patient response. It is essential to follow the prescribed regimen closely and not to exceed recommended dosages without medical supervision.
Benefits:
- Cancer Treatment: Erleva is effective in the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer, particularly in patients with EGFR mutations.
- Targeted Therapy: Erlotinib specifically targets the EGFR, a protein that is overexpressed in many cancer types, thereby inhibiting cancer cell growth and proliferation.
- Improved Survival Rates: Erleva treatment has been shown to improve overall survival rates and progression-free survival in patients with advanced or metastatic NSCLC and pancreatic cancer.
- Well-Tolerated: Erleva is generally well-tolerated, with manageable side effects such as rash, diarrhea, and fatigue reported infrequently, allowing for improved treatment adherence and patient comfort.
It is important to note that Erleva should only be used under the supervision of a qualified healthcare professional experienced in the management of cancer. Patients should be monitored regularly for treatment response and potential side effects, and appropriate supportive care should be provided as needed throughout the course of treatment.
Reviews
There are no reviews yet.